162 related articles for article (PubMed ID: 36916193)
21. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
22. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
23. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
24. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
27. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Shah AP; Patel CN; Sureja DK; Sanghavi KP
Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
[TBL] [Abstract][Full Text] [Related]
28. Inducing synthetic lethality using PARP inhibitors.
Boss DS; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
[TBL] [Abstract][Full Text] [Related]
29. AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
Armstrong DK
Gynecol Oncol; 2023 Apr; 171():162-163. PubMed ID: 36528399
[No Abstract] [Full Text] [Related]
30. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
[TBL] [Abstract][Full Text] [Related]
31. Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Eakin CM; Norton TJ; Monk BJ; Chase DM
Gynecol Oncol; 2020 Nov; 159(2):581-587. PubMed ID: 32972786
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Foo T; George A; Banerjee S
Genes Chromosomes Cancer; 2021 May; 60(5):385-397. PubMed ID: 33382149
[TBL] [Abstract][Full Text] [Related]
35. NADP
Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
[TBL] [Abstract][Full Text] [Related]
36. PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
Konstantinopoulos PA; Lheureux S; Moore KN
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-16. PubMed ID: 32364757
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
38. How safe is rucaparib in ovarian cancer?
Cosgrove CM; O'Malley DM
Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
[No Abstract] [Full Text] [Related]
39. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
